Opinion|Videos|March 4, 2025
Future Treatment Considerations for Multiple Myeloma
Panelists discuss how they approach sequencing therapy for relapsed/refractory multiple myeloma, considering all approved and investigational agents, and the factors that guide their treatment choices. They also explore the future directions of the later-stage relapsed/refractory multiple myeloma space, time permitting.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Considering all the agents (approved and in development), how do you approach sequencing therapy?
- How would you choose? What are the factors you consider?
- Where is the later-stage R/R MM space headed (time permitting)?
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
An OncLive Scientific Interchange and Workshop covered sequencing, toxicity management, and access barriers for CAR T-cell therapy in multiple myeloma.
Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.
The FDA accepted a new drug application for mezigdomide plus carfilzomib and dexamethasone for relapsed/refractory multiple myeloma.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA approved subcutaneous isatuximab delivered via an on-body injector for multiple myeloma.
Advertisement
Advertisement
Trending on OncLive
1
Experts Unpack Crucial Hematologic Oncology Data From ASCO 2026
2
International Intel: A Glance at the Top Global Breast Cancer News From April-June 2026
3
MYTHOS Misses Prespecified ORR End Point With T-DXd in HER2-Low Salivary Gland Carcinoma
4
Orelabrutinib Generates Significant Survival Benefits in Treatment-Naive CLL
5